Ozempic maker Novo mulls taking on hair loss

Company seeks to expand its direct-to-consumer pharmaceuticals business

Novo CEO Mike Doustdar. Novo Nordisk is eyeing the hair-loss market as the maker of Ozempic seeks to expand its direct-to-consumer pharmaceuticals business. Picture: Bloomberg

Novo Nordisk is eyeing the hair-loss market as the maker of Ozempic seeks to expand its direct-to-consumer pharmaceuticals business.

The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its scientific expertise or with the skill it has recently built in selling prescription drugs directly to consumers.